Abstract
We have conducted a broad phase II clinical trial a chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. Objective responses were noted only in 15% of the patients with melanoma and in 11% of the patients with non-Hodgkin's lymphoma. Significant leukopenia and thrombocytopenia were observed only in previously treated patients. Chlorozotocin does not appear to offer clinically significant advantages over other currently available nitrosoureas.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1229-1230 |
| Number of pages | 2 |
| Journal | Cancer Treatment Reports |
| Volume | 66 |
| Issue number | 5 |
| State | Published - Sep 20 1982 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors'. Together they form a unique fingerprint.
Cite this
Silver, B. A., Barlock, A. L., Lippman, M. E., Anderson, T., & Fisher, R. I. (1982). Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors. Cancer Treatment Reports, 66(5), 1229-1230.